Reshma Kewalramani

Asia Leaders

Reshma Kewalramani Broadened Vertex Beyond Cystic Fibrosis. Launch Economics Are the Next Clinical Test

Reshma Kewalramani has placed high-value rare-disease medicines, internally discovered small molecules, gene editing and disciplined reinvestment of cystic-fibrosis cash flow at the centre of the strategy. The next phase will test capital discipline, execution and durability across Asia.

Asia Leaders

Reshma Kewalramani Has Opened Vertex's Fourth Franchise. Kidney Medicine Must Now Match the Cystic Fibrosis Standard

Vertex is building beyond cystic fibrosis, with kidney medicine its newest large opportunity. Reshma Kewalramani must turn povetacicept into a durable franchise.